- Home
- LEXX vs INKT Comparison
LEXX vs INKT Comparison
Compare LEXX & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- INKT
- Stock Information
- Founded
- LEXX 2004
- INKT 2017
- Country
- LEXX Canada
- INKT United States
- Employees
- LEXX N/A
- INKT N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- LEXX Health Care
- INKT Health Care
- Exchange
- LEXX Nasdaq
- INKT Nasdaq
- Market Cap
- LEXX 39.1M
- INKT 36.7M
- IPO Year
- LEXX N/A
- INKT 2021
- Fundamental
- Price
- LEXX $1.45
- INKT $10.10
- Analyst Decision
- LEXX Strong Buy
- INKT Strong Buy
- Analyst Count
- LEXX 2
- INKT 2
- Target Price
- LEXX $9.50
- INKT $6.50
- AVG Volume (30 Days)
- LEXX 110.6K
- INKT 70.0K
- Earning Date
- LEXX 04-08-2025
- INKT 03-20-2025
- Dividend Yield
- LEXX N/A
- INKT N/A
- EPS Growth
- LEXX N/A
- INKT N/A
- EPS
- LEXX N/A
- INKT N/A
- Revenue
- LEXX $496,923.00
- INKT N/A
- Revenue This Year
- LEXX $30.72
- INKT N/A
- Revenue Next Year
- LEXX $31.85
- INKT N/A
- P/E Ratio
- LEXX N/A
- INKT N/A
- Revenue Growth
- LEXX 77.63
- INKT N/A
- 52 Week Low
- LEXX $1.38
- INKT $4.56
- 52 Week High
- LEXX $6.85
- INKT $19.00
- Technical
- Relative Strength Index (RSI)
- LEXX 33.85
- INKT 54.73
- Support Level
- LEXX $1.38
- INKT $8.97
- Resistance Level
- LEXX $1.72
- INKT $9.98
- Average True Range (ATR)
- LEXX 0.12
- INKT 1.44
- MACD
- LEXX -0.01
- INKT -0.07
- Stochastic Oscillator
- LEXX 12.85
- INKT 42.97
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.